Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PFE (Pfizer) How high will it go? -- Ignore unavailable to you. Want to Upgrade?

To: BigKNY3 who wrote (5092)	8/22/1998 12:57:00 PM
From: WS_DE	Respond to of 9523

BigKNY3: Thanks a lot for all these information!! <eom>

To: BigKNY3 who wrote (5092)	8/23/1998 12:16:00 PM
From: mauser96	Respond to of 9523

Great post. The eventual market for Cox 2 inhibitor type NSAD will be huge. In addition to the arthritis indication, NSAIDS are useful in a variety of conditions ranging from headaches to backaches. I believe that present drugs in this class kill about 7000 people a year in this country, mostly from GI bleeding. Personally, I'm very reluctant to take them. The old NSAID market would vanish overnight except for one factor- much of medicine today is concerned more with saving money than saving patients. It will take a lot of time and patient education before people insist on this (presumably) safer type drug.